Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic natural killer (NK) cell therapies for autoimmune diseases and cancer. Its lead program, AlloNK (AB-101), is a cryopreserved, off-the-shelf NK cell therapy designed to work with monoclonal antibodies to enhance B-cell depletion through ADCC. The company is currently focused on refractory rheumatoid arthritis as its lead autoimmune indication, while also evaluating AlloNK in other B-cell driven autoimmune diseases such as Sjögren’s disease. Artiva has built a cGMP manufacturing center in San Diego to support clinical supply, process optimization, and future commercial production if its programs are approved.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenueAlloNK (AB-101), an allogeneic, non-genetically modified NK cell therapy intended to enhance antibody-driven B-cell depletion.
Ongoing trials and regulatory work for autoimmune disease indications, especially refractory rheumatoid arthritis and Sjögren’s disease.
Internal and partner-supported manufacturing, cryopreservation, fill-finish, and clinical supply logistics for cell therapy products.
Customers
Artiva does not yet sell approved products commercially, so its current 'customers' are primarily clinical trial sites, collaborators, and future pharmaceutical partners rather than end patients. In the near term, the company’s programs are bought into by investigators, trial sponsors, and partner companies that need AlloNK supply for combination studies and clinical development. If approved, the commercial customer base would shift to physicians, hospitals, and specialty treatment centers serving patients with refractory autoimmune disease or certain cancers. The company also depends on contract manufacturing and logistics partners that support production, storage, and distribution of frozen cell therapy product.
They use AlloNK in ongoing studies to generate efficacy, safety, and dose-response data needed for regulatory advancement.
Hospitals and specialty clinics would administer AlloNK if approved for refractory rheumatoid arthritis or related autoimmune indications.
Partners may combine AlloNK with monoclonal antibodies or other agents to broaden development and commercialization reach.
Patients are the ultimate end users, especially those with B-cell driven diseases that have not responded to standard therapies.
Strategy
Artiva’s near-term strategy is to advance AlloNK in refractory rheumatoid arthritis and use early clinical data to support a pivotal trial design discussion with the FDA in 2026. The company is also broadening its autoimmune basket trial work, which helps it test whether the same NK-cell mechanism can work across multiple B-cell driven diseases. Manufacturing is a strategic priority because the company has invested in its San Diego facility to improve process control, support clinical trials, and prepare for potential commercial launch. Following the termination of the Affimed collaboration, Artiva is likely to rely more heavily on internal execution and selective partnerships to extend its pipeline and commercial options.
RA is the lead indication and the clearest path to a registrational strategy for AlloNK.
A multi-indication profile could improve the commercial opportunity and reduce dependence on one disease.
Cell therapy commercialization depends on reliable, scalable, cGMP-compliant production and cold-chain logistics.
Geography
Artiva is headquartered in the United States and operates its manufacturing center in San Diego, California. The company’s current business is concentrated in U.S.-based research, clinical development, and manufacturing activities, with no disclosed country-level revenue breakdown in the provided filings. Its collaboration history includes U.S. and certain other countries under the Affimed agreement, although that collaboration was terminated in 2025 after Affimed entered insolvency. Geography matters mainly because clinical trials, regulatory interactions, and manufacturing quality systems are all anchored in the U.S., while future commercialization could require broader international supply and regulatory execution.
Risks
Artiva faces the classic risks of a clinical-stage biotech company: no approved products, no product sales, and a need to fund expensive development for an uncertain period. Its lead program depends on successful clinical results, regulatory alignment, and the ability to manufacture cell therapy product without contamination or supply interruptions. Competition is intense across allogeneic NK, CAR-NK, CAR-T, and bispecific antibody platforms, so weak efficacy or safety data could quickly reduce partnering and commercialization prospects. The company also faces execution risk from its reliance on specialized manufacturing, cold-chain logistics, and third-party collaborators, as shown by the termination of the Affimed collaboration after Affimed’s insolvency.
- Clinical development failure for AlloNKImpact: CriticalLikelihood: Medium
The company’s value depends heavily on positive safety and efficacy data in refractory RA and other autoimmune indications.
Exposure: Lead program and main pipeline asset
- Manufacturing contamination or supply disruptionImpact: HighLikelihood: Medium
Cell therapy production is sensitive to microbial or viral contamination and biologic raw material shortages, which can halt trials.
Exposure: San Diego facility and external supply chain
- Capital dilution and funding shortfallImpact: HighLikelihood: Medium
The company expects continued operating losses and will need additional financing before any product revenue is possible.
Exposure: Corporate liquidity and development timeline
- Competitive displacementImpact: HighLikelihood: Medium
Many biotech and pharma companies are pursuing allogeneic NK, CAR-T, CAR-NK, and bispecific approaches in overlapping indications.
Exposure: Autoimmune and oncology pipeline positioning
- Collaboration and counterparty riskImpact: MediumLikelihood: Medium
The terminated Affimed collaboration shows that partner distress can remove a development path and reduce external support.
Exposure: Combination therapy development
Accounting
Judgemental itemsAny collaboration revenue depends on contract terms and delivery of support services, so timing can be uneven and non-recurring.
Impact: Affects reported revenue and comparability across quarters
Clinical and manufacturing vendors often bill after services are performed, requiring estimates for unpaid obligations at period end.
Impact: Affects operating expenses and current liabilities
Payments made before services are received are deferred until the underlying work is performed.
Impact: Affects timing of expense recognition and cash flow interpretation
As the San Diego site ramps, rent, maintenance, insurance, and supplies will increasingly shape overhead and gross development economics.
Impact: Affects operating expense trajectory and future margin profile
Similar listed companies
Publicly listed companies with a comparable business focus.
Arcturus Therapeutics Holdings Inc.
ARCT · Pharmaceutical Preparations
Arcus Biosciences, Inc.
RCUS · Pharmaceutical Preparations
Arcus Biosciences is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and, to a lesser extent, inflammatory and autoimmune diseases.
Q32 Bio Inc.
QTTB · Pharmaceutical Preparations
Alector, Inc.
ALEC · Biological Products, (No Diagnostic Substances)
Calidi Biotherapeutics, Inc.
CLDWW · Biological Products, (No Diagnostic Substances)
Nkarta, Inc.
NKTX · Pharmaceutical Preparations
Last updated: 24/09/2026